Tests a team-based medicine reduction program in adults with chronic kidney disease
Tests a team-led plan to safely stop some medicines in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Deprescribing Intervention for Patients With Chronic Kidney Disease
Key facts
- Where
- Doha, QatarSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced kidney disease who are on hemodialysis or are followed in a low clearance clinic in Qatar. It tests a team-led program to review and reduce medicines.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- End-stage kidney disease (ESRD) treated with hemodialysis, or pre-dialysis patients followed at a low clearance clinic.
- Earlier treatment
- Must have been treated at one of the ambulatory kidney centers in Qatar for at least two months.
Main reasons for not taking part
- Unstable condition or a psychiatric condition
- Uncontrolled behaviors or exit-seeking behaviors
- Critically ill, pregnant, mentally ill, dementia, or unconscious patients, and children
- Limited life expectancy (less than 6 months)
Read by machine on 9 November 2026.
Where in Qatar
- Hamad Medical CorporationDoha, QatarTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hamad Medical Corporation
- Trial code
- NCT06324045
- Record updated
- 1 October 2025
- Original description
Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented.Read full original descriptionShow less
Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial
Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented.
In general, there are limited deprescribing initiatives in CKD settings. There is a need to provide evidence of the impact of deprescribing programs on improving clinical and economic outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing deprescribing programs in clinical settings. Therefore, we have built a team of researchers, clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit into the Qatar healthcare system. This project aims to initiate a deprescribing multidisciplinary team and to evaluate the impact of providing such services on the clinical and economic outcomes among CKD patients in Qatar using a randomized controlled trial approach. The findings could have a potential positive impact on the professional practice and patient safety represented by health and economic outcomes.
Inclusion: Patients who are:; diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic; receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months; able to communicate in Arabic and/or English.
Exclusion: Unstable or has a psychiatric condition; Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients; Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger); Patients with limited life expectancy (less than 6 months).